AI is revolutionizing the way we develop medicines
Artificial intelligence is giving the pharmaceutical world a major upgrade.
At GSK in London, researchers use AI tools like Phenformer to connect genetic data with diseases, while Boston's Insilico Medicine relies on AI to develop drugs faster, like its new treatment for lung disease.
Thanks to these smart systems, finding and creating potential medicines now takes way less time.
AI's impact on clinical trials and future investments
AI isn't just about discovering drugs; it's also making clinical trials more efficient.
Tools like GSK's Cogito Forge help design better studies, and digital twins (basically virtual patients) mean fewer real people are needed in control groups.
With pharma companies teaming up with tech firms, investments in AI for drug development could hit $15 billion by 2030, all aiming to bring new therapies to people sooner.